Marcaine (Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. This prevents sodium influx, halting the generation and propagation of nerve impulses, which results in a reversible loss of sensation in the targeted area.

The appropriate dose of Marcaine is determined by the prescribing clinician based on the specific procedure, patient weight, age, and clinical condition. Healthcare providers calculate the dose to achieve effective analgesia while minimising the risk of systemic toxicity.

Safety data for bupivacaine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only considered when the potential benefit justifies any potential risk, and it should be discussed with a qualified healthcare professional.

To order Marcaine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Compared with shorter‑acting agents such as lidocaine, bupivacaine (Marcaine) offers a longer duration of analgesia, often lasting several hours. Ropivacaine provides a similar duration with a slightly lower cardiotoxic profile, while bupivacaine remains a common choice for procedures requiring prolonged nerve block.

Marcaine should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and follow aseptic techniques when preparing the injection to maintain sterility.

Marcaine is administered by a qualified healthcare professional via injection. It can be delivered epidurally for spinal analgesia, infiltrated directly into tissues for local anaesthesia, or injected intra‑articularly to control postoperative joint pain. The route and technique are selected according to the clinical indication.

Serious risks include cardiovascular toxicity such as arrhythmias or cardiac arrest, central nervous system toxicity leading to seizures or respiratory depression, and severe allergic reactions including anaphylaxis. Prompt recognition and emergency management, including lipid emulsion therapy, are essential if these events occur.

Marcaine should be avoided in patients with known hypersensitivity to bupivacaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or significant hepatic impairment. It is also contraindicated when used in conjunction with other agents that markedly increase the risk of systemic toxicity.